173 related articles for article (PubMed ID: 38160212)
1. Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.
Sánchez-Castillo A; Heylen E; Hounjet J; Savelkouls KG; Lieuwes NG; Biemans R; Dubois LJ; Reynders K; Rouschop KM; Vaes RDW; De Keersmaecker K; Lambrecht M; Hendriks LEL; De Ruysscher DKM; Vooijs M; Kampen KR
Br J Cancer; 2024 Mar; 130(4):568-584. PubMed ID: 38160212
[TBL] [Abstract][Full Text] [Related]
2. Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis-Addicted Breast Tumor Growth.
Geeraerts SL; Kampen KR; Rinaldi G; Gupta P; Planque M; Louros N; Heylen E; De Cremer K; De Brucker K; Vereecke S; Verbelen B; Vermeersch P; Schymkowitz J; Rousseau F; Cassiman D; Fendt SM; Voet A; Cammue BPA; Thevissen K; De Keersmaecker K
Mol Cancer Ther; 2021 Jan; 20(1):50-63. PubMed ID: 33203732
[TBL] [Abstract][Full Text] [Related]
3.
Fan TWM; Bruntz RC; Yang Y; Song H; Chernyavskaya Y; Deng P; Zhang Y; Shah PP; Beverly LJ; Qi Z; Mahan AL; Higashi RM; Dang CV; Lane AN
J Biol Chem; 2019 Sep; 294(36):13464-13477. PubMed ID: 31337706
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer.
Zhang X; Cheung RM; Komaki R; Fang B; Chang JY
Clin Cancer Res; 2005 Sep; 11(18):6657-68. PubMed ID: 16166445
[TBL] [Abstract][Full Text] [Related]
5. Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α.
Biziotis OD; Tsakiridis EE; Ali A; Ahmadi E; Wu J; Wang S; Mekhaeil B; Singh K; Menjolian G; Farrell T; Abdulkarim B; Sur RK; Mesci A; Ellis P; Berg T; Bramson JL; Muti P; Steinberg GR; Tsakiridis T
Mol Oncol; 2023 Nov; 17(11):2235-2256. PubMed ID: 37584455
[TBL] [Abstract][Full Text] [Related]
6. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.
Dai Y; Wei Q; Schwager C; Moustafa M; Zhou C; Lipson KE; Weichert W; Debus J; Abdollahi A
Radiother Oncol; 2015 Feb; 114(2):173-81. PubMed ID: 25592111
[TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer.
Yu D; Yang P; Lu X; Huang S; Liu L; Fan X
Cell Commun Signal; 2023 Jul; 21(1):169. PubMed ID: 37430270
[TBL] [Abstract][Full Text] [Related]
9. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.
van den Heuvel MM; Verheij M; Boshuizen R; Belderbos J; Dingemans AM; De Ruysscher D; Laurent J; Tighe R; Haanen J; Quaratino S
J Transl Med; 2015 Jan; 13():32. PubMed ID: 25622640
[TBL] [Abstract][Full Text] [Related]
10. MiR-181a reduces radiosensitivity of non-small-cell lung cancer via inhibiting PTEN.
Chen Y; Liao W; Yuan A; Xu H; Yuan R; Cao J
Panminerva Med; 2022 Sep; 64(3):374-383. PubMed ID: 32506887
[TBL] [Abstract][Full Text] [Related]
11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
12. Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response.
Kuo P; Bratman SV; Shultz DB; von Eyben R; Chan C; Wang Z; Say C; Gupta A; Loo BW; Giaccia AJ; Koong AC; Diehn M; Le QT
Clin Cancer Res; 2014 Nov; 20(21):5558-69. PubMed ID: 25189484
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer.
Zhu L; Xue F; Xu X; Xu J; Hu S; Liu S; Cui Y; Gao C
J Cell Biochem; 2018 Sep; 119(9):7873-7886. PubMed ID: 29943841
[TBL] [Abstract][Full Text] [Related]
14. SIRT6 through PI3K/Akt/mTOR signaling pathway to enhance radiosensitivity of non-Small cell lung cancer and inhibit tumor progression.
Xiong L; Tan B; Lei X; Zhang B; Li W; Liu D; Xia T
IUBMB Life; 2021 Sep; 73(9):1092-1102. PubMed ID: 34033225
[TBL] [Abstract][Full Text] [Related]
15. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
16. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.
Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
Grabauskiene S; Bergeron EJ; Chen G; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
J Surg Res; 2014 Mar; 187(1):6-13. PubMed ID: 24418519
[TBL] [Abstract][Full Text] [Related]
18. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.
Storozhuk Y; Hopmans SN; Sanli T; Barron C; Tsiani E; Cutz JC; Pond G; Wright J; Singh G; Tsakiridis T
Br J Cancer; 2013 May; 108(10):2021-32. PubMed ID: 23632475
[TBL] [Abstract][Full Text] [Related]
19. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
[TBL] [Abstract][Full Text] [Related]
20. Transcription factor NKX2-1 drives serine and glycine synthesis addiction in cancer.
Heylen E; Verstraete P; Van Aerschot L; Geeraerts SL; Venken T; Timcheva K; Nittner D; Verbeeck J; Royaert J; Gijbels M; Uyttebroeck A; Segers H; Lambrechts D; Cools J; De Keersmaecker K; Kampen KR
Br J Cancer; 2023 May; 128(10):1862-1878. PubMed ID: 36932191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
